ArticleInvestigational new drugs2013

The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.

Mohamed A Khalil et al.PubMed ↗Publisher ↗

No numbers read from the abstract.